Documents Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with...

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis1…

Documents 1 Komrokji RS et al. Proc ASH 2011;Abstract 282.

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis1…

Documents Alessandro M. Vannucchi Section of Hematology , University of Florence, Italy

Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and Without JAK2 Mutation Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and…